ArticleFrontiers in public health2026
Economic burden of
Article in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Methods: A multicenter cross-sectional study was performed in Jinhua, China. Between October 2024 and March 2025, patients with laboratory-confirmed MP infection were enrolled using a multistage stratified random sampling approach. Data regarding direct, indirect, and intangible costs were collected via structured questionnaires and hospital information systems. Univariate analyses and generalized linear models (GLM) with a gamma distribution and log link function were employed to explore factors associated with the economic burden of MP infection. Results: A total of 582 patients were included, comprising 372 outpatients and 210 inpatients. The mean total cost per inpatient (¥6,289.21) was 7.69 times higher than that of outpatients (¥817.66). Among outpatients, direct and indirect medical costs contributed almost equally to the total expenditure, whereas inpatient costs were dominated by direct medical expenses. The median intangible cost was ¥5,000 for outpatients and ¥8,000 for inpatients. GLM analysis showed that prolonged disease duration, higher household income, and payment method were significantly associated with increased economic burden ( Conclusion:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.